Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ginsenoside Rh2 (Rh2), an important phytochemical derived from , has demonstrated anticancer activity, amelioration of ischemic brain injury, and mitigation of doxorubicin-induced cardiac damage. The cardioprotective effects of Rh2 were evaluated in a mouse model of acute myocardial infarction (AMI). Mice received Rh2 treatment for 14 days postsurgery, and the cardiac function was assessed by echocardiography. Rh2 treatment significantly improved left ventricular function, reduced infarct size, and suppressed cardiac fibrosis in the MI model. Furthermore, it promoted angiogenesis in the border zone, enhanced mitochondrial membrane potential and ATP production, and reduced hypoxia-induced ROS accumulation, excessive mitochondrial fission, and cardiomyocyte apoptosis. In vitro, Rh2 enhanced human umbilical vein endothelial cell (HUVEC) migration in wound-healing assays, an effect associated with an increased level of ERK phosphorylation. These effects were abolished by U0126, an ERK inhibitor. In conclusion, Rh2 protects against MI-induced cardiac injury by improving mitochondrial bioenergetics and activating an ERK-dependent pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jafc.5c00479 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis.
Front Oncol
August 2025
Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Introduction: Prostate cancer (PC), the most common male genitourinary malignancy and second leading cause of global cancer deaths in men, frequently progresses to lethal castration-resistant PC (CRPC). Ginsenoside Rh2 (GRh2), a ginseng-derived bioactive compound, exhibits antitumor potential, but its efficacy and mechanisms in PC remain unclear.
Methods: PC3 cells were treated with GRh2 to assess proliferation (IC50 calculation), migration, and invasion.
Targeting the TRIB3-MYC axis in cancer: mechanistic insights and therapeutic disruption strategies.
Invest New Drugs
September 2025
Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Universidad Autónoma de Madrid, Módulo 13, 28049, Madrid, Spain.
The oncogenic transcription factor MYC drives proliferation, metabolism, and therapy resistance in the majority of human cancers, yet its large, nuclear protein-protein interface has long frustrated direct drug discovery. A pivotal breakthrough was the identification of Tribbles pseudokinase 3 (TRIB3) as a high-affinity scaffold that binds the helix-loop-helix/leucine zipper region of MYC, blocks the E3-ubiquitin-ligase, UBE3B, from tagging critical lysines, and thereby prolongs MYC protein half-life while enhancing MYC-MAX transcriptional output. This review integrates structural, biochemical, and in vivo data to show how genetic deletion or pharmacological eviction of TRIB3 collapses MYC levels, silences its gene program, and suppresses tumor growth in B-cell lymphomas and selected solid tumors.
View Article and Find Full Text PDFGinsenoside Rh2 ameliorates pulmonary fibrosis via HSP70-dependent autophagic flux regulation and senescence arrest.
J Ethnopharmacol
August 2025
College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials, Jilin Agricultural University, Changchun, 130118, China; College of Life Sciences, Engineering Research Center of the Chinese Ministry of
Ethnopharmacological Relevance: Panax ginseng C.A. Meyer, a prominent Qi-tonifying herb in Traditional Chinese Medicine (TCM), has been traditionally used to enhance spleen and pulmonary functions through Qi regulation, consistent with the TCM doctrine of "fortifying vital qi while dispelling pathogens".
View Article and Find Full Text PDFSurface-Engineered Nanoshuttles Hijack Macrophages In Vivo to Boost Blood-Brain Barrier Penetration and Immunomodulation for Targeted Glioblastoma Therapy.
ACS Nano
August 2025
College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Institute of Molecular and Nano Science, Shandong Normal Un
Macrophage-hitchhiking drug delivery across the blood-brain barrier (BBB) has garnered considerable attention for its potential in glioblastoma (GBM) treatment. However, challenges such as the complexity of in vitro synthesis and the risk of macrophage polarization toward protumor phenotypes hinder its practical application. We developed a receptor ligand-free nanoshuttle that can hitchhike on macrophages in vivo for efficient BBB penetration and targeted drug delivery while inducing macrophage polarization toward antitumor phenotypes for GBM therapy.
View Article and Find Full Text PDFNanoparticle conjugation of ginsenoside Rh2 enhanced antitumor efficacy on hepatocellular carcinoma.
Sci Rep
August 2025
Department of Acupuncture, Physiotherapy and Rehabilitation, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jingwu Road 324#, Jinan, 250021, China.
Ginsenoside Rh2 (Rh2) is one of the main bioactive ginsenosides that act as a natural antitumor drug. However, the clinical application of Rh2 is limited by its low solubility in water. In this study, a novel ginsenoside Rh2 pH-sensitive liposome was constructed for targeted liver cancer therapy.
View Article and Find Full Text PDF